DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphoglycerate kinase 1 (PGK1) — PGK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9FDF · 1.44 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
Ehlers-Danlos syndrome is a heterogenous group of connective tissue disorders. Seven clinical types had been identified by 1982, with underlying biochemical defects defined for types IV through VII. Molecular genetics research by 2010 had linked mutations in the COL5A1, COL5A2, TNXB, COL3A1, PWD1, COL1A1, COL1A2 and ADAMTS-2 genes to EDS. The major clinical features are hyperextensibility of skin, hypermobility of the joints, generalised connective tissue fragility, and delayed wound healing with formation of atrophic scars. The hypermobile form, which has no biological marker, is by far the most often encountered.
Diagnosis is frequently delayed. A 2025 case study reports a 35-year-old woman whose EDS diagnosis was established 17 years after symptom onset, despite numerous specialist consultations. The authors attribute this to fragmented care and a focus on isolated symptoms without a holistic approach. They argue that early detection shortens time to diagnosis, improves patient quality of life, and optimises healthcare resource utilisation. A 2017 paper states that despite its high frequency, EDS remains practically unknown to doctors, who evoke many other diagnoses, primarily mental disorders that sometimes lead to hospitalisations in psychiatry.
For patients with major vascular complications, a 1982 paper notes that most have few of the commonly recognised musculoskeletal and cutaneous abnormalities. It suggests that recognition of the correct diagnosis and application of accepted vascular surgical techniques may improve morbidity and mortality. No controlled trial data on any pharmacological treatment for EDS are presented in these abstracts. What is still missing is systematic evidence on drug interventions, coordinated diagnostic pathways that have been tested in prospective studies, and any validated stratification of patients by genetic subtype to guide management.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Surgery · 1982 · 62 citations
Vascular Manifestations in Patients With Ehlers-Danlos Syndrome
AbstractEhlers-Danlos syndrome (EDS) is clinically and genetically a heterogenous disorder of connective tissue synthesis. Seven clinical types of this disease have been identified and the underlying biochemical defects defined in types IV through VII. Unfortunately, most patients with major vascular complications of EDS have few, if any of the commonly recognized musculoskeletal and cutaneous abnormalities. Recognition of the correct diagnosis and the application of accepted vascular surgical techniques may improve the morbidity and mortality for these patients.
Journal of Depression & Anxiety · 2017 · 4 citations
Ehlers-Danlos-Tschernogobow Syndrome: A Frequent, Rarely Diagnosed Disease whose Patients are often the Victim of an Abusive Psychiatrization
AbstractDespite its high frequency, Ehlers-Danlos disease remains practically unknown to doctors who evoke many other diagnoses with dangerous therapeutic and social consequences. These diagnoses primarily include mental disorders that sometimes lead to hospitalizations in psychiatry. Progression of the disease’s clinical knowledge allows for a diagnosis of certainty, based solely on clinical examination, in the absence of biological marker in the hypermobile form, which is by far the most often encountered.
AbstractEhlers-Danlos syndrome (EDS) comprises a heterogeneous group of rare hereditary connective tissue diseases, of which the major clinical features are hyperextensibility of skin, hypermobility of the joints, generalized connective tissue fragility, and delayed wound healing with formation of atrophic scars. The disease is divided into six clinical types. Molecular genetics research showed that the mutations in COL5A1 gene, COL5A2 gene, TNXB gene, COL3A1 gene, PWD1 gene, COL1A1 gene, COL1A2 gene and ADAMTS-2 gene are linked to EDS.
Key words:
Ehlers-Danlos syndrome; Virulence gene
Journal of Health Statistics Reports · 2025 · 0 citations · open access
The Importance of Early Diagnosis of Ehlers-Danlos Syndrome – A Case Study and Public Health Perspective
AbstractEhlers-Danlos Syndrome (EDS) is a rare, inherited connective tissue disorder, frequently diagnosed with significant delay due to fragmented care and lack of coordination among specialists. We present the case of a 35-year-old woman whose EDS diagnosis was established 17 years after the onset of symptoms. Despite numerous specialist consultations, the focus on isolated symptoms without a holistic approach led to prolonged diagnostic neglect. This case highlights the crucial role of the family physician as a care coordinator, integrating clinical data from various fields and adopting a holistic view of the patient. Early detection of rare diseases such as EDS is vital for public health—it shortens the time to diagnosis, improves patient quality of life, and optimizes healthcare resource utilization. Our analysis underscores the urgent need for systemic solutions: better care coordination, development of integrated medical data tools, and enhanced education of physicians in rare diseases, especially at the primary care level.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
